Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Unknown 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Carcinoma, Hepatocellular 57Stomach Neoplasms 45Carcinoma, Non-Small-Cell Lung 36Colorectal Neoplasms 24Esophageal Squamous Cell Carcinoma 19Rectal Neoplasms 11Lung Neoplasms 11Esophageal Neoplasms 11Nasopharyngeal Carcinoma 10Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Cholangiocarcinoma 6Uterine Cervical Neoplasms 5Small Cell Lung Carcinoma 5Triple Negative Breast Neoplasms 4Recurrence 4Liver Neoplasms 4Endometrial Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Carcinoma 3Breast Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3Turcot syndrome 2

Interventions

Injections 27Carboplatin 18Docetaxel 14pembrolizumab 13Paclitaxel 12Bevacizumab 10durvalumab 8Nivolumab 8Cisplatin 8Fluorouracil 7Pemetrexed 6Oxaliplatin 6Leucovorin 6trifluridine tipiracil drug combination 5toripalimab 5tislelizumab 5linifanib 5Capecitabine 5zimberelimab 4talazoparib 4olaparib 4fludarabine 4Panobinostat 4Itraconazole 4Irinotecan 4Gemcitabine 4Everolimus 4tremelimumab 3sotorasib 3sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Advanced Solid Tumors × sintilimab × Clear all
NCT05718219 2025-08-13

Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1 Active not recruiting
408 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT05164458 2023-12-28

Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Unknown
320 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT03545971 2023-02-28

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
53 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡